A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis. Issue 6 (6th May 2020)

• Record Type: Journal Article
• Authors: Gonçalves, Céline S.; Xavier‐Magalhães, Ana; Martins, Eduarda P.; Pinto, Afonso A.; Pires, Manuel Melo; Pinheiro, Célia; Reis, Rui M.; Sousa, Nuno; Costa, Bruno M.
• Is Part Of: Molecular oncology. Volume 14:Issue 6(2020)
• Page Start: 1224
• Page End: 1241
• Publication Date: 2020-05-06
• Subjects: DNA methylation -- glioma -- homeobox -- HOX -- regulation -- WNT pathway; Cancer -- Molecular aspects -- Periodicals; 616.994005
• DOI: 10.1002/1878-0261.12633
• Languages: English
• ISSNs: 1574-7891

Abstract

Abstract : Despite much effort to improve treatments, patients with malignant glioma still present a very poor prognosis that has not changed significantly in the last decades. In this context, it is crucial to better understand glioma pathogenesis to identify new molecular prognostic subgroups and therapeutic targets. WNT6 was recently identified as a new oncogenic molecule in glioblastoma (GBM), with prognostic value in patients, but the mechanisms underlying WNT6 aberrant expression in glioma are still unknown. WNT6 was overexpressed in a subset of gliomas independently of IDH mutations, 1p/19q codeletion status, and WNT6 gene copy number. Interestingly, WNT6 expression is associated with the DNA methylation levels of particular CpG regions at both the WNT6 promoter and the gene body in glioma patient samples. HOXA9, a transcription factor previously associated with poorer clinical outcome in GBM, was identified as a novel transcriptional regulator of WNT6, activating the WNT/β‐catenin pathway in vitro and in vivo . In various cohorts of glioma patients, mRNA levels of WNT6 and HOXA9 were significantly correlated, extending our in vitro and in vivo findings into the clinical setting. Interestingly, this novel molecular link between WNT6 and HOXA9 was not limited to glioma, as they were co‐expressed also in patients with other tumor types. Clinically, WNT6 was a prognostic biomarker of shorter survival in GBM, independently of HOXA9 expression. Concomitant high expression of both WNT6 and HOXA9 identified a subgroup of patients with particularly dismal survival. These findings describe novel WNT6 regulatory mechanisms in GBM, establishing particular DNA methylation patterns and HOXA9 as critical regulators of WNT6 expression in glioma. This HOXA9‐WNT6 molecular link supports WNT signaling in GBM cells and is a powerful prognostic biomarker, highlighting the clinical relevance of this axis in patients. Novel therapies targeting WNT6‐HOXA9 signaling may thus be useful for this deadly disease. Abstract : This work highlights DNA methylation and the homeobox HOXA9 protein as critical regulators of WNT6 expression in malignant glioma. The concomitant expression of HOXA9 and WNT6 results in overactivation of the WNT/β‐catenin signaling pathway in vitro and in vivo, and identifies a subgroup of glioblastoma patients with particularly dismal prognosis, suggesting this HOXA9‐WNT6 link may be an attractive therapeutic target.